Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.86 |
| ▸ | CA1 | P00915 | 5/20 | 0.84 |
| ▸ | CA2 | P00918 | 5/20 | 0.84 |
| ▸ | CA12 | O43570 | 3/20 | 0.84 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.84 |
| ▸ | CA7 | P43166 | 2/20 | 0.84 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10892940 | 0.97 | PPARA (0.91) | PPARACA1CA2CA12CA14 | |
| SCHEMBL3792249 | 0.97 | PPARA (0.91) | PPARACA1CA2CA12CA14 | |
| SCHEMBL9285865 | 0.97 | PPARA (0.91) | PPARACA1CA2CA12CA14 | |
| SCHEMBL3120899 | 0.93 | PPARA (1.00) | PPARACA1CA2CA12CA14 | |
| SCHEMBL18644318 | 0.93 | PPARA (1.00) | PPARACA1CA2CA12CA14 | |
| SCHEMBL3117611 | 0.93 | PPARA (1.00) | PPARACA1CA2CA12CA14 | |
| SCHEMBL3119510 | 0.93 | PPARA (1.00) | PPARACA1CA2CA12CA14 | |
| Butyl(Butylsulfamoyl)Amine SCHEMBL2486301 | 0.92 | CA1 (1.00) | PPARACA1CA2CA12CA14 | |
| SCHEMBL3803009 | 0.91 | PPARA (0.79) | PPARACA1CA2CA12CA14 | |
| SCHEMBL21693509 | 0.87 | PPARA (0.68) | PPARACA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1962641-A | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-05-16 | — | — | CN | claimed |
| EP-1370556-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | claimed |
| EP-1404798-A4 | PREPARATION OF CELLULOSIC MATERIALS | NOVOZYMES NORTH AMERICA INC (US) | 2004-08-04 | — | — | EP | claimed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | claimed |
| CN-1509273-A | Metalloproteinase inhibitors | — | 2004-06-30 | — | — | CN | claimed |
| CN-1509275-A | Metalloproteinase inhibitors | — | 2004-06-30 | — | — | CN | claimed |
| US-20040116486-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | claimed |
| US-20040110809-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | claimed |
| EP-1404798-A1 | PREPARATION OF CELLULOSIC MATERIALS | Novozymes North America, Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | claimed |
| EP-1370538-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | claimed |
| EP-1370535-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | claimed |
| US-20030046773-A1 | Preparation of cellulosic materials | NOVOZYMES NORTH AMERICA, INC. | 2003-03-13 | — | — | US | claimed |
| WO-2003002705-A1 | PREPARATION OF CELLULOSIC MATERIALS | NOVOZYMES NORTH AMERICA, INC. (US) | 2003-01-09 | — | — | WO | claimed |
| WO-2002074752-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | claimed |
| WO-2002074749-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | claimed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | claimed |
| EP-0084718-B1 | TRIPHENDIOXAZINE DYESTUFFS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-04-16 | — | — | EP | claimed |
| US-4565648-A | FOR PRODUCTION OF POLYURETHANES | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-21 | — | — | US | claimed |
| EP-0075230-B1 | ANAEROBICALLY CURABLE ADHESIVE | Teroson GmbH (DE) | 1984-06-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110809-A1 | Metalloproteinase inhibitors | MMP9, MMP2, MMP3 | PPARA 4256/4885CA1 362/4885CA2 341/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | PPARA 3432/4885CA1 134/4885CA2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.